Investing

CRISPR Therapeutics : CRSP

CRSP

Stock Data

$56.88

$1.30 (2.23%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

CRISPR Therapeutics AG is at the forefront of gene editing, pioneering treatments for serious diseases through its CRISPR/Cas9 technology. This innovative approach allows for precise DNA modifications, offering hope in areas like hemoglobinopathies, immune-oncology, autoimmune diseases, and type 1 diabetes. Its leading therapy, CASGEVY, aims to transform care for patients with severe blood disorders through gene-edited cell therapy. Additionally, the company is developing cutting-edge CAR T cell therapies and in vivo gene editing solutions, working in strategic partnerships to advance its mission of curing complex diseases.

All CRISPR Therapeutics Articles

44 Articles

Trey Thoelcke | Jul 23, 2025 at 8:45 AM EDT

2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now

While insider buying has been slow lately, there have been some notable, large purchases at a couple of biotech companies,…

Ian Cooper | Jul 22, 2025 at 9:25 AM EDT

Nearly 89% of Companies are Seeing Insider Selling, But these 3 are Seeing Substantial Buying

Insiders have become bearish. In fact, according to MarketWatch, “Corporate insiders have taken a sharply pessimistic turn – selling their…

Rich Duprey | Jun 15, 2025 at 6:34 AM EDT

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require…

Rich Duprey | Apr 24, 2025 at 1:14 PM EDT

Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a…

Rich Duprey | Mar 28, 2025 at 9:29 AM EDT

1 Top Technology ETF to Buy and 1 to Avoid

The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The…

Rich Duprey | Oct 31, 2024 at 9:30 AM EDT

Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied…

Chris MacDonald | Oct 2, 2024 at 4:25 PM EDT

Cathie Wood Stocks (CRSP, SHOP, SQ) Could Actually Be Darn Good Picks

Cathie Wood is the founder and CEO of Ark Invest, an asset management firm focusing on disruptive innovation, with approximately…

Rich Duprey | Sep 8, 2024 at 12:32 PM EDT

2 Biotech Bets to Buy in September

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or…

Trey Thoelcke | Aug 22, 2024 at 9:15 AM EDT

Prediction: This Health Care Stock Will Be the Best Performer the Rest of 2024

With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for…

Joshua Rodriguez | Jul 17, 2024 at 9:22 AM EDT

Add These 5 Hot Biotech Stocks In July

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in…

Kristin Hitchcock | Jul 5, 2024 at 1:15 AM EDT

Forget Intuitive Surgical: This Stock Is the Next Millionaire Maker

Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.…

Trey Thoelcke | Feb 29, 2024 at 10:15 AM EST

CEO Dumps 20 Million Ginkgo Bioworks Shares

Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround…

Lee Jackson | May 31, 2023 at 8:54 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: Abbott Labs, Boston Scientific, ChargePoint, Coinbase, Dollar General, Equitrans, Ford, Hasbro, Johnson & Johnson, Kenvue, Medtronic and More

Wednesday's top analyst upgrades and downgrades included Abbott Laboratories, Boston Scientific, ChargePoint, Coinbase Global, Dollar General, Equitrans Midstream, Ford, Hasbro,…

Lee Jackson | Apr 14, 2023 at 8:55 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: American Airlines, Broadcom, Chevron, DraftKings, Exxon Mobil, Hertz, McDonald’s, Merck, Meta, Shopify and More

Friday's top analyst upgrades and downgrades included American Airlines, Broadcom, Chevron, DraftKings, Enphase Energy, EOG Resources, Exxon Mobil, First Solar,…

Chris Lange | Aug 10, 2022 at 10:51 AM EDT

Barclays Picks 2 Winners and 2 Losers After Earnings

Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.